The study’s chief investigator said it was still too early to know how effective it was.
London:
The results of late-stage trials of the University of Oxford’s COVID-19 vaccine candidate should definitely be known by Christmas, the study’s chief researcher said on Thursday, adding that it was still too early to tell. know its effectiveness.
When asked if it was too early to say whether the vaccine, which is licensed at AstraZeneca, stops the development of the disease, Andrew Pollard, director of the Oxford Vaccine Group, said: “We don’t. aren’t quite there yet. isn’t going to rush that. “
“We are getting closer, and it will certainly be before Christmas, based on progress,” he told BBC Radio when asked when trial investigators would not be blind to efficacy data and published results.
(Except for the title, this story was not edited by GalacticGaming staff and is posted from a syndicated feed.)
